Education
About Us
Working with TipRanks
Follow Us
Orion Corporation (GB:0M2O)
LSE:0M2O
0M2O Stock Chart & Stats
Day’s Range― - ―
52-Week Range€41.43 - €72.00
Previous CloseN/A
Volume5.12K
Average Volume (3M)20.39K
Market Cap
€9.70B
Enterprise Value€9.12B
Total Cash (Recent Filing)€259.40M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)25.8
Beta0.90
Next Earnings
Oct 28, 2025EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.59
Shares Outstanding109,162,500
10 Day Avg. Volume18,330
30 Day Avg. Volume20,389
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
EarningsNubeqa is expected to drive consensus EPS upgrades, improving Orion's ability to raise the dividend, which is crucial for local investors.
Product PortfolioOpevesostat (ODM-208) could sustain growth into the 2030s, with potential peak sales of €1.1 billion and Orion eligible to receive $1.6 billion in milestones.
Sales OutlookNubeqa's peak sales are projected to reach €1.3 billion, backed by Bayer's optimistic outlook, positive doctor feedback, and strong IQVIA script trends.
Bears Say
CompetitionNubeqa faces competition from Xtandi and Erleada, although it is preferred by doctors for better tolerability and flexibility in use with comorbidities.
Orion Corporation News
0M2O FAQ
What was Orion Corporation’s price range in the past 12 months?
Orion Corporation lowest share price was €41.43 and its highest was €72.00 in the past 12 months.
What is Orion Corporation’s market cap?
Orion Corporation’s market cap is €9.70B.
When is Orion Corporation’s upcoming earnings report date?
Orion Corporation’s upcoming earnings report date is Oct 28, 2025 which is in 60 days.
How were Orion Corporation’s earnings last quarter?
Orion Corporation released its earnings results on Jul 18, 2025. The company reported €0.59 earnings per share for the quarter, beating the consensus estimate of €0.518 by €0.072.
Is Orion Corporation overvalued?
According to Wall Street analysts Orion Corporation’s price is currently Overvalued.
Does Orion Corporation pay dividends?
Orion Corporation does not currently pay dividends.
What is Orion Corporation’s EPS estimate?
Orion Corporation’s EPS estimate is 0.65.
How many shares outstanding does Orion Corporation have?
Orion Corporation has 109,162,500 shares outstanding.
What happened to Orion Corporation’s price movement after its last earnings report?
Orion Corporation reported an EPS of €0.59 in its last earnings report, beating expectations of €0.518. Following the earnings report the stock price went up 5.035%.
Which hedge fund is a major shareholder of Orion Corporation?
Currently, no hedge funds are holding shares in GB:0M2O
Company Description
Orion Corporation
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
Technical Analysis
Ownership Overview
―
Insiders
5.97%
Mutual Funds
― Other Institutional Investors
82.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---